Company intelligence / Profile preview

Cidat

San Diego, California, United Statescidara.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Cidara is developing targeted immunotherapies using its proprietary Cloudbreak platform to create drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Drug-Fc conjugates (DFCs)ImmunotherapiesAnti-infectives
Industry: Biotech

Drug pipeline

1 asset

hydralazine

Phase 1

Indications: Cancer

Partnerships

Johnson & JohnsonJanssen Pharmaceuticals, Inc.WuXi XDC

Beyond the preview

Go deeper on Cidat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cidat.

Explore the full profile